SCHEMBL30788371

SCHEMBL30788371

CC(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(N)=O

nearest known ligand 0.62

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ IL23R Q5VWK5 1/20 0.62
▸ TFPI P10646 5/20 0.61
▸ CXCR4 P61073 2/20 0.60
▸ NMUR2 Q9GZQ4 3/20 0.58
▸ NMUR1 Q9HB89 3/20 0.58
▸ OPRM1 P35372 6/20 0.56
▸ OPRK1 P41145 6/20 0.56
▸ RAMP3 O60896 1/20 0.55
▸ CALCR P30988 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30788356 0.96 TFPI (0.61) IL23RTFPICXCR4NMUR2NMUR1
SCHEMBL30788363 0.93 NMUR2 (0.59) IL23RTFPICXCR4NMUR2NMUR1
SCHEMBL30788368 0.92 NMUR2 (0.58) IL23RTFPICXCR4NMUR2NMUR1
SCHEMBL30753756 0.92 NMUR2 (0.61) IL23RTFPICXCR4NMUR2NMUR1
SCHEMBL30788366 0.92 C5AR1 (0.58) IL23RTFPICXCR4OPRM1OPRK1
SCHEMBL30788346 0.91 TFPI (0.56) IL23RTFPICXCR4NMUR2NMUR1
SCHEMBL30788369 0.91 C5AR1 (0.57) IL23RTFPICXCR4OPRM1OPRK1
SCHEMBL30788354 0.90 TFPI (0.55) IL23RTFPICXCR4NMUR2NMUR1
SCHEMBL30788338 0.90 F2 (0.58) IL23RTFPICXCR4CALCR
SCHEMBL17722482 0.89 TFPI (0.68) TFPICXCR4NMUR2NMUR1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240139089-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS GLO PHARMA, INC. 2024-05-02 — — US disclosed
US-20240122823-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS GLO PHARMA, INC. 2024-04-18 — — US disclosed
US-20240076314-A1 PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY GLO PHARMA, INC. 2024-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139089-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS LIPA, PLIN5, PLIN3 IL23R 2181/4885TFPI 3801/4885CXCR4 3507/4885
US-20240076314-A1 PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY CHRNB1, CHRNG, CHRNA1 IL23R 1502/4885TFPI 2394/4885CXCR4 1494/4885
US-20240122823-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS LIPA, PLIN5, LIPE IL23R 3023/4885TFPI 4016/4885CXCR4 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback